Delivering oncology RWE that informs HTA and access decisions across borders
Flatiron FORUM (Fostering Oncology RWE Uses and Methods) is a global consortium among life sciences companies, HTA bodies, and academic experts.
FORUM’s mission is to advance the use of real-world evidence (RWE) in health technology assessments and regulatory decisions. By developing and applying rigorous methodologies, FORUM enables decision-making to bring innovative therapies to patients faster.
Founded by Flatiron Health and driven in collaboration with life sciences leaders, HTA bodies, and academic institutions, FORUM is solving a central challenge in oncology RWE: how to generate credible, transportable insights across borders — efficiently, transparently, and at scale.
our approach
Flatiron FORUM sets the pace: Building a better standard for global real-world evidence in oncology research, starting with a focus on Transportability
Flatiron FORUM, in collaboration with leading HTA bodies, top pharmaceutical companies, and global academic and clinical experts, co-author high-impact publications that are shaping the future of cancer decision-making. Together with industry and regulatory leaders, we continue to amplify our presence and influence across the oncology landscape.
As part of our ongoing efforts, we have advanced the understanding of how real-world evidence can be leveraged to demonstrate the transportability of outcomes across countries and are continually exploring new opportunities to use RWE and cutting-edge methods to advance oncology research and care.
Key publications, to date
Manuscripts
BMJ Open
November 2024
Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study
Seamus Kent1, Philani Mpofu2,Stephen Duffield3, Jane Adam3, Brennan Beal2,Trevor J Royce2, Blythe Adamson2,4, Jyotsna Kasturi2, Arun Sujenthiran1,Páll Jónsson3
1. Flatiron Health UK Ltd, London, UK 2. Flatiron Health Inc, New York, USA 3. National Institute for Health and Care Excellence (NICE), Manchester, UK 4. The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, Washington, USA
PharmacoEconomics
October 2023
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments
Alex J. Turner1, Cormac Sammon1, Nick Latimer2,3, Blythe Adamson4, Brennan Beal4, Vivek Subbiah5,Keith R. Abrams6,7, Joshua Ray8
1. Putnam PHMR, London, UK 2. School of Health and Related Research, University of Shefeld, Shefeld, UK 3. Delta Hat, Nottingham, UK 4. Flatiron Health, New York, NY, USA 5. Sarah Cannon Research Institute, Nashville, TN, USA 6. Department of Statistics, University of Warwick, Coventry,UK 7. Centre for Health Economics, University of York, York, UK 8. Global Access, F. Hofmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
BMJ Open
September 2023
Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study
Philani Mpofu1, Seamus Kent2, Páll Jónsson3, Harlan Pittell1, Brad Groves4,Ivy Altomare1, Amanda Copeland1, Shrujal Baxi1, Danielle Bargo1,Arun Sujenthiran2,Blythe Adamson1,5
1. Flatiron Health Inc, New York, USA 2. Flatiron Health UK Ltd, London, UK 3.Data Analytics, National Institute for Health and Care Excellence (NICE), Manchester, UK 4. Managed access Team, NICE, Manchester, UK 5. University of Washington, Seattle, Washington, USA
Protocols
ISPOR RWE Registry
18 July 2024
US-England (Flatiron/NCRAS) de Novo mBC Transportability Study Protocol and Statistical Analysis Plan
Caitlin Clunie-O'Connor, Blythe Adamson, Elsie Horne, Philani Brian Mpofu, Harlan Pittell, Vanessa Acquaah
ISPOR RWE Registry
11 November 2024
US-Germany Transportability Study (Flatiron Health/GermanOncology) Protocol
Caitlin Clunie-O'Connor, Philani Brian Mpofu, Elspeth Horne, Blythe Adamson, Harlan Pittell, Amit Samani, Christoph Buhl, Arun Sujenthiran, Qianyi Zhang, Vanessa Acquaah
ISPOR RWE Registry
16 December 2024
US-Germany (Flatiron/GermanOncology) Multiple Myeloma Transportability Study Protocol and Statistical Analysis Plan
Caitlin Clunie-O'Connor, Elspeth Horne, Vanessa Acquaah
ISPOR RWE Registry
24 April 2025
US-Austria (Flatiron/AGMT) mBC Transportability Study Protocol and Statistical Analysis Plan
Vanessa Acquaah, Harlan Pittell, Philani Brian Mpofu, Elsie Horne, Blythe Adamson
Sample poster presentations
ISPOR EU 2024
November 2024
Transporting real-world evidence: Is it possible to transport OS estimates in HER2+ mBC from US to UK?
Mpofu, P., Thuresson, P.-O., Sanglier, T., Horne, E., Pittell, H., Samani, A., Buhl, C., Sujenthiran, A., Tchakoute, C., Clunie-O'Connor, C., & Adamson, B.
ISPOR EU 2024
November 2024
Transportability of overall survival estimates from the US to England in metastatic breast cancer using nationally representative data sources
Pittell, H., Horne, E., Mpofu, P., Thuresson, P. O., Jiao, X., Mokiou, S., Sanglier, T., Tchakoute, C., Samani, A., Zhang, Q., Buhl, C., Sujenthiran, A., Sadetsky, N., Kaushik, A., Jose, S., Clunie-O'Connor, C., & Adamson, B
Events
Flatiron FORUM consistently presents at roundtables and a broad range of additional public forums, shaping FORUM’s strategy and oncology RWE in the broader scientific community to elevate thought leadership.
Participation in Flatiron FORUM generates critical evidence and delivers outsized value to life sciences members
Flatiron FORUM members actively shape research protocols, influence publication strategy, and ensure every project aligns with your oncology goals while driving RWE innovation globally.
Benefits include:
-
Design and lead applied methods research alongside regulators and experts
-
Gain early visibility into global market access trends and evidence needs
-
Collaborate on multinational data from Flatiron’s network in the U.S., U.K., Germany, and Japan
-
Participate in industry roundtables and private working sessions
Let’s shape the future of oncology real-world evidence.
Join Flatiron FORUM to lead, innovate, and advance cancer research.
-
Position your organisation at the forefront of real-world evidence innovation.
-
Gain exclusive access to global data, industry insights, and leadership roundtables
-
Directly influence study protocols, publication strategy, and industry thought leadership while ensuring evidence aligns with your portfolio.
Get in touch